Antithrombotic Therapy and Cardiovascular Outcomes After Transcatheter Aortic Valve Replacement in Patients With Atrial Fibrillation.

[1]  J. Leipsic,et al.  Transcatheter Aortic‐Valve Replacement with a Balloon‐Expandable Valve in Low‐Risk Patients , 2019, The New England journal of medicine.

[2]  Andrew S. Mugglin,et al.  Transcatheter Aortic‐Valve Replacement with a Self‐Expanding Valve in Low‐Risk Patients , 2019, The New England journal of medicine.

[3]  A. Vora,et al.  Challenges in Aortic Stenosis: Review of Antiplatelet/Anticoagulant Therapy Management with Transcatheter Aortic Valve Replacement (TAVR): TAVR with Recent PCI, TAVR in the Patient with Atrial Fibrillation, and TAVR Thrombosis Management , 2018, Current Cardiology Reports.

[4]  B. Gersh,et al.  Impact of atrial fibrillation on outcomes of patients treated by transcatheter aortic valve implantation: A systematic review and meta-analysis. , 2017, American heart journal.

[5]  K. Mahaffey,et al.  Adjuvant Antithrombotic Therapy in TAVR , 2017, Current Cardiology Reports.

[6]  S. Kaul,et al.  2017 ACC Expert Consensus Decision Pathway for Transcatheter Aortic Valve Replacement in the Management of Adults With Aortic Stenosis: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. , 2017, Journal of the American College of Cardiology.

[7]  V. Rajagopal,et al.  Neurological Events Following Transcatheter Aortic Valve Replacement and Their Predictors: A Report From the CoreValve Trials , 2016, Circulation. Cardiovascular interventions.

[8]  B. García del Blanco,et al.  Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement. , 2016, JACC. Cardiovascular interventions.

[9]  J. Leipsic,et al.  One-Year Clinical Outcomes With SAPIEN 3 Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Severe Aortic Stenosis , 2016, Circulation.

[10]  J. Leipsic,et al.  Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis , 2016, The Lancet.

[11]  M. Mack,et al.  Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. , 2016, The New England journal of medicine.

[12]  E. Antman,et al.  Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial , 2016, Journal of the American Heart Association.

[13]  M. Mack,et al.  Relation of frailty to outcomes after transcatheter aortic valve replacement (from the PARTNER trial). , 2015, The American journal of cardiology.

[14]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[15]  G. Dangas,et al.  Stroke After Transcatheter Aortic Valve Replacement: Incidence, Risk Factors, Prognosis, and Preventive Strategies , 2014, Clinical cardiology.

[16]  B. Iung,et al.  The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties. , 2014, European heart journal.

[17]  D. Atar,et al.  Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. , 2014, European heart journal.

[18]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[19]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[20]  L. Nombela‐Franco,et al.  Clinical and prognostic implications of existing and new-onset atrial fibrillation in patients undergoing transcatheter aortic valve implantation , 2013, Journal of Thrombosis and Thrombolysis.

[21]  J. Leipsic,et al.  Timing, Predictive Factors, and Prognostic Value of Cerebrovascular Events in a Large Cohort of Patients Undergoing Transcatheter Aortic Valve ImplantationClinical Perspective , 2012 .

[22]  M. Mack,et al.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, Journal of the American College of Cardiology.

[23]  Sanjay Kaul,et al.  2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. , 2012, Journal of the American College of Cardiology.

[24]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[25]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[26]  Stuart J Pocock,et al.  Transcatheter versus surgical aortic-valve replacement in high-risk patients. , 2011, The New England journal of medicine.

[27]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[28]  Salim Yusuf,et al.  Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[29]  S. Susen,et al.  Identification of tissue factor in experimental aortic valve sclerosis. , 2009, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[30]  E. Tremoli,et al.  Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[31]  S. Yusuf,et al.  Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range , 2008, Circulation.

[32]  R Simon,et al.  A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. , 1984, Statistics in medicine.